Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.

Targeted therapies directed against individual cancer-specific molecular alterations offer the development of disease-specific and individualized treatment strategies. Activation of the transcription factor E2F-1 via alteration of the p16-cyclinD-Rb pathway is one of the key molecular events in the development of gliomas. E2F-1 binds to and activates the E2F-1 promoter in an autoregulatory manner. The human E2F-1 promoter has been shown to be selectively activated in tumor cells with a defect in the pRb pathway. Paradoxically, E2F-1 also carries tumor suppressor function. Our investigations focused on analyzing the dynamics of the activity of the E2F-1 responsive element under basal conditions and certain stimuli such as chemotherapy using molecular imaging technology. We constructed a retrovirus bearing the Cis-E2F-TA-LITG reporter system to noninvasively assess E2F-1-dependent transcriptional regulation in culture and in vivo. We show that our reporter system is sensitive to monitor various changes in cellular E2F-1 levels and its transcriptional control of our reporter system to follow the state of the Rb/E2F pathway and the DNA damage-induced up-regulation of E2F-1 activity in vivo. Exposure to 1,3-bis(2-chloroethyl)-1-nitrosourea leads to increased E2F-1 expression levels in a dose- and time-dependent manner, which can be quantified by imaging in vivo, leading to an alteration of cell cycle progression and caspase 3/7 activity. In summary, noninvasive imaging of E2F-1 as a common downstream regulator of cell cycle progression using the Cis-E2F-TA-LUC-IRES-TKGFP reporter system is highly attractive for evaluating the kinetics of cell cycle regulation and the effects of novel cell cycle targeting anticancer agents in vivo.

[1]  M. Christmann,et al.  Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. , 2007, Cancer research.

[2]  S. Kang,et al.  Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. , 2007, Stem cells and development.

[3]  P. Schirmacher,et al.  Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. , 2007, Gastroenterology.

[4]  B. Anandh,et al.  Altered structure and deregulated expression of the tumor suppressor gene retinoblastoma (RB1) in human brain tumors , 2007, Molecular and Cellular Biochemistry.

[5]  David G Johnson,et al.  Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context. , 2006, Current molecular medicine.

[6]  David G Johnson,et al.  Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. , 2006, Current molecular medicine.

[7]  N. L. La Thangue,et al.  DNA‐damage‐responsive acetylation of pRb regulates binding to E2F‐1 , 2006, EMBO reports.

[8]  M. Oren,et al.  Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F , 2005, Cell Death and Differentiation.

[9]  E. Holland,et al.  Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model , 2004, Nature Medicine.

[10]  N. L. La Thangue,et al.  The emerging role of E2F-1 in the DNA damage response and checkpoint control. , 2004, DNA repair.

[11]  H. A. Rogoff,et al.  Life, Death, and E2F: Linking Proliferation Control and DNA Damage Signaling via E2F1 , 2004, Cell cycle.

[12]  S. Lowe,et al.  Reversing Drug Resistance In Vivo , 2004, Cell cycle.

[13]  John T. Powers,et al.  E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. , 2004, Molecular cancer research : MCR.

[14]  H. A. Rogoff,et al.  Apoptosis Associated with Deregulated E2F Activity Is Dependent on E2F1 and Atm/Nbs1/Chk2 , 2004, Molecular and Cellular Biology.

[15]  K. Helin,et al.  E2F7, a novel E2F featuring DP‐independent repression of a subset of E2F‐regulated genes , 2003, The EMBO journal.

[16]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[17]  W. Kaelin.  E2F1 as a target: promoter-driven suicide and small molecule modulators. , 2003, Cancer biology & therapy.

[18]  W. Heiss,et al.  Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes. , 2003, Human gene therapy.

[19]  Motoo Nagane,et al.  Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. , 2002, Cancer research.

[20]  C. Steer,et al.  Unbound E2F modulates TGF-β1-induced apoptosis in HuH-7 cells , 2002 .

[21]  K. Tsukuda,et al.  An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. , 2002, Cancer research.

[22]  F. McCormick,et al.  Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. , 2002, Cancer cell.

[23]  D. Nettelbeck,et al.  Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. , 2002, Cancer research.

[24]  J Humm,et al.  Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Nevins,et al.  Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. , 2001, Genes & development.

[26]  J. Cairncross,et al.  Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. , 2001, Cancer research.

[27]  Xin Lu,et al.  Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb , 2000, Oncogene.

[28]  T. McDonnell,et al.  A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo , 2000, Oncogene.

[29]  A. Jacobs,et al.  Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. , 1999, Neoplasia.

[30]  D. Banerjee,et al.  Role of E2F-1 in chemosensitivity. , 1998, Cancer research.

[31]  Fred H. Gage,et al.  Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.

[32]  Z. Ram,et al.  Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells , 1997, Nature Medicine.

[33]  P. Wen,et al.  Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector , 1997, Nature Medicine.

[34]  T. Sladek.  E2F transcription factor action, regulation and possible role in human cancer. , 1997 .

[35]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[36]  V P Collins,et al.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.

[37]  W. Sellers,et al.  A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Bartek,et al.  Unrestricted cell cycling and cancer , 1995, Nature Medicine.

[39]  A. Aguzzi,et al.  Transgenic and gene disruption techniques in the study of neurocarcinogenesis , 1995, Glia.

[40]  W. Kaelin,et al.  Transcriptional control by E2F. , 1995, Seminars in cancer biology.

[41]  J. Nevins,et al.  Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. , 1994, Genes & development.

[42]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[43]  S. Hassenbusch,et al.  BCNU stability as a function of ethanol concentration and temperature , 1991, Journal of Neuro-Oncology.

[44]  P. Roux,et al.  MoMuLV-derived self-inactivating retroviral vectors possessing multiple cloning sites and expressing the resistance to either G418 or hygromycin B. , 1990, Biochimie.

[45]  P. Kantoff,et al.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Deen,et al.  Differential response to elutriated 9L cells to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea. , 1981, Cancer research.

[47]  R. Tobey.  Different drugs arrest cells at a number of distinct stages in G2 , 1975, Nature.

[48]  H. Crissman,et al.  Comparative effects of three nitrosourea derivatives on mammalian cell cycle progression. , 1975, Cancer research.

[49]  B. Teicher,et al.  Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents , 2000, Cancer Chemotherapy and Pharmacology.

[50]  W. El-Deiry,et al.  p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. , 1999, International journal of oncology.

[51]  R. Müller,et al.  Cell cycle-regulated transcription in mammalian cells. , 1995, Progress in cell cycle research.